CN106176589A - Improve the medicinal composition for injections of quinidine sulfate drug injection preparation stability - Google Patents
Improve the medicinal composition for injections of quinidine sulfate drug injection preparation stability Download PDFInfo
- Publication number
- CN106176589A CN106176589A CN201610646225.3A CN201610646225A CN106176589A CN 106176589 A CN106176589 A CN 106176589A CN 201610646225 A CN201610646225 A CN 201610646225A CN 106176589 A CN106176589 A CN 106176589A
- Authority
- CN
- China
- Prior art keywords
- quinidine sulfate
- injection
- injections
- malic acid
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses the medicinal composition for injections improving quinidine sulfate drug injection preparation stability, mainly it is dissolved in water for injection by quinidine sulfate, adding the medicinal composition for injections that malic acid and/or natrium malicum are made as pH adjusting agent regulation medicinal liquid pH value, the consumption of described malic acid and/or natrium malicum is 1g～5g/100ml.The present invention can make this injection pH value more stable, quinidine sulfate degradation material relatively prior art is substantially reduced, in the case of avoiding using other to increase the cosolvent of clinical practice risk, improve the clarity of quinidine sulfate injection, particularly solving quinidine sulfate injection uses prior art products to occur the problem that small particles, white block, solution are muddy in the case of period of storage is longer, can ensure that the visible foreign matters inspection of product meets the regulation of drug standard, it is simple to clinical application and popularization.
Description
Technical field
The invention belongs to pharmaceutical technology field, in particular it relates to improve quinidine sulfate drug injection preparation stability
Medicinal composition for injections.
Background technology
Quinidine sulfate is mainly used in paroxysmal tachycardia, tremble in atrium, morning is won；Prevent ventricular tachycardia and to room
Room knot reciprocal tachycardia；Also can prevent Symptomatic supraventricular and ventricular premature contraction.
Due to quinidine sulfate dissolubility extreme difference in aqueous, therefore it is made into quinidine sulfate hydrochlorate or sulphuric acid
Quinidine phosphate is to increase its water solublity.Presently commercially available quinidine sulfate injection mainly have quinidine sulfate hydrochlorate,
The phosphatic injection with small volume of quinidine sulfate, and in quinidine sulfate hydrochlorate, quinidine sulfate phosphate solution
The high-capacity injection that addition glucose or sodium chloride are made as osmotic pressure regulator.But when preparing above-mentioned injection, must
The pH value of medicinal liquid need to be adjusted to be suitable for the certain limit that human injection is administered, and the pH value regulator that current document report uses is equal
For sodium hydroxide solution or use hydrochloric acid solution, phosphoric acid solution, but use quinidine sulfate note prepared by above-mentioned pH value regulator
Penetrate liquid under the conditions of storage for a long time and winter low temperature, easily separate out the precipitate such as tiny white point, white block, solution muddiness, cause product
Visible foreign matters check item defective.Prior art is that addition polyoxyethylene sorbitan monoleate is as cosolvent, to solve product in the solution
The sedimentary problems such as small particles, white block, solution are muddy occur.But polyoxyethylene sorbitan monoleate is owing to having the effect of haemolysis and blood pressure lowering,
And easily become sour in storage and autoclaving process, cause the injection clinical practice risk containing polyoxyethylene sorbitan monoleate higher,
Make troubles to clinical application and popularization.
Summary of the invention
The technical problem to be solved is to provide the injection improving quinidine sulfate drug injection preparation stability
Pharmaceutical composition.This medicinal composition for injections employing malic acid, natrium malicum are as pH adjusting agent, and pass through creative labor
When dynamic discovery uses malic acid, natrium malicum as pH adjusting agent, medicinal liquid pH value is more stable, and quinidine sulfate degradation material is relatively
Prior art is substantially reduced, and in the case of avoiding using other to increase the cosolvent of clinical practice risk, solves satisfactorily
Quinidine sulfate injection of having determined easily separates out tiny white point, white block, solution muddiness under the conditions of storage for a long time and winter low temperature
Problem.
The present invention solves the problems referred to above and be the technical scheme is that raising quinidine sulfate drug injection preparation stability
Medicinal composition for injections, be mainly dissolved in water for injection by quinidine sulfate, add osmotic pressure regulator, and add malic acid
And/or the medicinal composition for injections that natrium malicum is made as pH adjusting agent regulation medicinal liquid pH value, described malic acid and/or Herba Marsileae Quadrifoliae
The consumption of fruit acid sodium is 1g～5g/100ml.
Described osmotic pressure regulator is any one or a few in glucose, sodium chloride, xylitol, mannitol, fructose.
The consumption of osmotic pressure regulator is prior art, and sodium chloride consumption is 0.7g/100ml；Glucose, xylitol, mannitol, fructose
Consumption is 5g/100ml～10g/100ml.
The concentration of described quinidine sulfate is calculated as 10mg～10g/100ml with quinidine sulfate.
Described medicinal liquid pH value is 4.0～68.0.
Described quinidine sulfate drug injection preparation formulation is injection.
The preparation method of the medicinal composition for injections of above-mentioned raising quinidine sulfate drug injection preparation stability, including
Following step:
(1) quinidine sulfate 5g～100g, malic acid and/or natrium malicum 1g～5g are weighed；
(2) malic acid, natrium malicum are configured to the solution of 1g/100ml～10g/100ml respectively, standby；
(3), during quinidine sulfate adds the water for injection 500ml of 30 DEG C～40 DEG C, stir to after being completely dissolved, the activity of addition
Charcoal, described activated carbon dosage is 0.15g/100ml, stirs 15 minutes, filters decarburization；
(4) step (3) gained filtrate step (2) configures malic acid and/or natrium malicum solution regulation pH value be 4.0～
6.0, add the water for injection of 30 DEG C～40 DEG C to 1000ml；
(5) by step (4) gained medical filtration to clarification, fill, sterilizing, to obtain final product.
In described step (1) malic acid consumption be 1g～5g, natrium malicum consumption be 1g～5g.
Described step also includes osmotic pressure regulator 7.0g in (1).
Described osmotic pressure regulator is sodium chloride.
In such scheme, what addition malic acid and/or natrium malicum referred to addition can be in malic acid, natrium malicum
Any one, or malic acid, natrium malicum are with arbitrary proportion proportioning；In step (2), the malic acid of addition, natrium malicum
In one, then make a kind of solution, as included malic acid, natrium malicum two kinds, be configured to solution for standby the most respectively；Sulphuric acid Kui
Buddhist nun's fourth, the consumption of osmotic pressure regulator can use the consumption of prior art, adjust according to the consumption of prior art.
In sum, the invention has the beneficial effects as follows: the present invention, by experimental studies have found that, notes at quinidine sulfate medicine
Penetrating in preparation, when using malic acid, natrium malicum as pH adjusting agent, medicinal liquid pH value is more stable, quinidine sulfate degradation product
Matter relatively prior art is substantially reduced, in the case of avoiding using other to increase the cosolvent of clinical practice risk, satisfactory
Solve quinidine sulfate injection and use prior art products easily to separate out tiny white point, white block, molten in storage process
The problem that liquid is muddy, it is ensured that keeping that quinidine sulfate injection can be stable in storage process is different seen from injection
Analyte detection meets the regulation of drug standard, it is simple to clinical application and popularization.
The present invention passes through creative work, to the tiny white point separated out in quinidine sulfate injection, white block, solution muddiness
Reason be analyzed and study, determine that deposit is mainly raw material free alkali crystallize and a small amount of catabolite, occur above-mentioned
Reason may be relevant with the kind of acid used by the pH value of solution and pH adjusting agent, alkali.Therefore natrium malicum is used to adjust as pH
Joint agent, and use malic acid as pH value counter regulation agent, avoiding using the feelings of the cosolvent of other increase clinical practice risks
Under condition, to solve this product easily tiny white point of precipitation, white block, muddy asking of solution under the conditions of long-term storage and winter low temperature
Topic.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described in further detail, but embodiments of the present invention are not limited to this.
Embodiment 1:
Improve the preparation method of the medicinal composition for injections of quinidine sulfate drug injection preparation stability, including following step
Rapid: (1) weighting raw materials is with quinidine sulfate extracting solution amount of calculation 25g, sodium chloride 7.0g, malic acid 2g, natrium malicum 4mg；
(2) malic acid, natrium malicum are configured to the solution of 10%～20% respectively, standby；(3) water for injection of less than 40 DEG C is added
In 500ml, stir to after being completely dissolved, add 0.02%(g/ml) activated carbon, stir 15 minutes, filtration decarburization；(4) filtrate
Regulating pH value with malic acid or natrium malicum solution is 3.0～7.0, adds the water for injection of less than 40 DEG C to 1000ml；(5) medicine
Liquid is filtered until clear, fill, and sterilizing to obtain final product.
Composition and the content thereof of the concrete each component of the present embodiment are as follows:
Quinidine sulfate extracting solution 25g
Sodium chloride 7.0g
Malic acid 2.0g
Natrium malicum 4.0g
Malic acid, natrium malicum are configured to the solution of 10%～20% respectively, standby.Quinidine sulfate extracting solution adds less than 40 DEG C
Water for injection 500ml in, stir to after being completely dissolved, add 0.15% activated carbon (i.e. activated carbon dosage is 0.2g/
100ml), stir 15 minutes, filter decarburization.Filtrate malic acid or natrium malicum solution regulation pH value are 4.0～6.0, add
The water for injection of less than 40 DEG C is to 1000ml.Medical filtration, to clarification, fill, sterilizing, to obtain final product.
Embodiment 2:
The present embodiment another embodiment, as follows, the note of above-mentioned raising quinidine sulfate drug injection preparation stability
Penetrate pharmaceutical composition to be prepared according to the following steps:
(1) weighting raw materials is with quinidine sulfate amount of calculation 70g, malic acid 3g, natrium malicum 6g；(2) malic acid, natrium malicum
It is configured to the solution of 10%～20% respectively, standby；(3) adding in the water for injection 500ml of less than 40 DEG C, stirring is to being completely dissolved
After, add 0.15%(g/ml) activated carbon, stir 15 minutes, filtration decarburization；(4) filtrate malic acid or natrium malicum solution
Regulation pH value is 4.0～6.0, adds the water for injection of less than 40 DEG C to 1000ml；(5) medical filtration is to clarification, fill, goes out
Bacterium, to obtain final product.
Composition and the content thereof of the concrete each component of the present embodiment are as follows:
Quinidine sulfate extracting solution 70g
Malic acid 3g
Natrium malicum 5g
Malic acid, natrium malicum are configured to the solution of 10%～20% respectively, standby.Hydrochloric acid quinidine sulfate adds less than 40 DEG C
In water for injection 500ml, stir to after being completely dissolved, add 0.15% activated carbon (i.e. activated carbon dosage is 0.15g/
100ml), stir 15 minutes, filter decarburization.Filtrate malic acid or natrium malicum solution regulation pH value are 4.0～6.0, add
The water for injection of less than 40 DEG C is to 1000ml.Medical filtration, to clarification, fill, sterilizing, to obtain final product.
Embodiment 3:
Quinidine sulfate injection stability comparative test
The visible foreign matters detection utilizing quinidine sulfate injection obtained by the present invention meets the regulation of drug standard, and molten
Liquid stability is fine, in the case of avoiding using other to increase the cosolvent of clinical practice risk, solves quinidine sulfate
Injection easily occurs the problems such as small particles, white block, solution are muddy in storage process.Utilize the sulphuric acid Kui Buddhist nun obtained by the present invention
Fourth injection is wanted according to the relevant of two annex Ⅺ Ⅹ C pharmaceutical preparation stability test guidelines of China's coastal port
Ask, investigated respectively to place to place for 24 months, 40 DEG C at 25 DEG C and within 6 months, 60 DEG C, placed 10 days, 0～5 DEG C of low temperature 20 days medicine of placement
Thing stability, result constant product quality at the conditions of the experiments described above, every Testing index all meets the rule of this product quality standard
Fixed.
The pharmacological results shows: utilize the stable quinidine sulfate injection obtained by the present invention without hemolytic, nothing
Anaphylaxis, nonirritant, meet the requirement of drug administration by injection.
According to the above results, the quinidine sulfate drug injection preparation of the present invention can improve quinidine sulfate injection
The clarity of liquid, particularly in the case of quinidine sulfate injection period of storage is longer, it is possible to stable holding injection
Visible foreign matters detection meets the regulation of drug standard, solves quinidine sulfate medicine and uses existing technical products when storage
Between longer in the case of the problem that small particles, white block, solution are muddy occurs, it is ensured that the visible foreign matters inspection of product meets medicine
The regulation of quality standard, it is simple to clinical application and popularization.
As it has been described above, just can preferably realize the present invention.
Claims (5)
1. improve the medicinal composition for injections of quinidine sulfate drug injection preparation stability, it is characterised in that main by sulfur
Acid quinidine is dissolved in water for injection, adds the note that malic acid and/or natrium malicum are made as pH adjusting agent regulation medicinal liquid pH value
Penetrating pharmaceutical composition, the consumption of described malic acid and/or natrium malicum is 1g～5g/100ml.
The medicinal composition for injections of raising quinidine sulfate drug injection preparation stability the most according to claim 1,
It is characterized in that, also include osmotic pressure regulator, described osmotic pressure regulator be glucose, sodium chloride, xylitol, mannitol,
Any one or a few in fructose.
The injectable drug combination of raising quinidine sulfate drug injection preparation stability the most according to claim 1 and 2
Thing, it is characterised in that the concentration of described quinidine sulfate is calculated as 0.1g～10g/100ml with quinidine sulfate.
The medicinal composition for injections of raising quinidine sulfate drug injection preparation stability the most according to claim 1,
It is characterized in that, described medicinal liquid pH value is 4.0～6.0.
The medicinal composition for injections of raising quinidine sulfate drug injection preparation stability the most according to claim 1,
It is characterized in that, described quinidine sulfate drug injection preparation formulation is injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610646225.3A CN106176589A (en) | 2016-08-09 | 2016-08-09 | Improve the medicinal composition for injections of quinidine sulfate drug injection preparation stability |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610646225.3A CN106176589A (en) | 2016-08-09 | 2016-08-09 | Improve the medicinal composition for injections of quinidine sulfate drug injection preparation stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106176589A true CN106176589A (en) | 2016-12-07 |
Family
ID=57513815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610646225.3A Withdrawn CN106176589A (en) | 2016-08-09 | 2016-08-09 | Improve the medicinal composition for injections of quinidine sulfate drug injection preparation stability |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176589A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101347429A (en) * | 2007-07-20 | 2009-01-21 | 重庆人本药物研究院 | Stable tartaric acid ifenprodil injection and method of preparing the same |
| CN102008727A (en) * | 2010-12-07 | 2011-04-13 | 四川升和药业股份有限公司 | Injection-purpose medicine composition for improving stability of ligustrazine medicine injection formulation and preparation method of injection-purpose medicine composition |
-
2016
- 2016-08-09 CN CN201610646225.3A patent/CN106176589A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101347429A (en) * | 2007-07-20 | 2009-01-21 | 重庆人本药物研究院 | Stable tartaric acid ifenprodil injection and method of preparing the same |
| CN102008727A (en) * | 2010-12-07 | 2011-04-13 | 四川升和药业股份有限公司 | Injection-purpose medicine composition for improving stability of ligustrazine medicine injection formulation and preparation method of injection-purpose medicine composition |
Non-Patent Citations (1)
| Title |
|---|
| 中国药物大全编委会: "《中国药物大全》", 31 January 1998 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105106110A (en) | Injectable medicine composition capable of improving stability of puerarin medicine injection preparation and preparation method of injectable medicine composition | |
| CN105125485A (en) | Preparation method of injecting drug improving stability of puerarin drug injection preparation | |
| CN105963247A (en) | Preparation method of injection medicine for improving stability of quercetin medicine injection preparation | |
| CN106361969A (en) | Preparation method of drug composition for improving stability of Shengmai drug injection preparation | |
| CN106176589A (en) | Improve the medicinal composition for injections of quinidine sulfate drug injection preparation stability | |
| CN106474056A (en) | A kind of medicinal composition for injections improving phylloxanthin drug injection preparation stability | |
| CN106389315A (en) | Injection pharmaceutical composition for improving stability of sharpleaf galangal fruit drug injection preparation | |
| CN106138211A (en) | A kind of medicinal composition for injections improving Radix Illicii Lanceolati drug injection preparation stability | |
| CN106214629A (en) | A kind of preparation method of breviscapine drug injection preparation stability compositions | |
| CN106176590A (en) | Improve the preparation method of quinidine sulfate ejection preparation stability composition | |
| CN106361693A (en) | Preparation method of leech injection preparation pharmaceutical composition | |
| CN105999278A (en) | Injecting medicine composition for improving stability of ginsenoside medicine injection | |
| CN106344502A (en) | Pharmaceutical composition for injection capable of improving stability of leech drug injection preparation | |
| CN106344636A (en) | Preparation method of Chinese thorowax root injection preparation pharmaceutical composition | |
| CN106265493A (en) | Improve the pharmaceutical composition of Codeine Hydrochloride drug injection preparation stability | |
| CN106377592A (en) | Pharmaceutical composition for injection capable of improving stability of Yinzhihuang medication injection agent | |
| CN106109404A (en) | A kind of medicinal composition for injections improving Caulis et folium stauntoniae drug injection preparation stability | |
| CN106389314A (en) | Method for preparing injection preparation medicine compositions with fructus alpiniae oxyphyllae | |
| CN106344503A (en) | Method for preparing pharmaceutical composition of lutein injection preparation | |
| CN107753571A (en) | A kind of medicinal composition for injections of decumbent corydalis tuber | |
| CN106344501A (en) | Pharmaceutical composition for injection capable of improving stability of berberine drug injection preparation | |
| CN106176588A (en) | Improve the preparation method of composition of Codeine Hydrochloride ejection preparation stability | |
| CN106109406A (en) | Improve the medicinal composition for injections of breviscapine drug injection preparation stability | |
| CN105902487A (en) | Injection pharmaceutical composition capable of improving stability of quercetin medication injection preparation | |
| CN106344506A (en) | Preparation method of berberine injection preparation pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161207 |